Simon Wright

Simon Wright EPA, CPA

Partner

Technology and Sector Specialisms

Biotechnology and Life SciencesDiagnostics and Personalised MedicinePharmaceuticalsRegenerative Medicine

Professional Qualifications

Member of the Institute of Professional Representatives before the European Patent Office (EPI), Chairman of the CIPA Life Sciences Committee, Secretary of the EPI Biotechnological Inventions Committee, Member of the CIPA Council, UK Member of EPI Council, Member of the Standing Advisory Committee before the European Patent Office (SACEPO), UK Member of EPI Governing Board

Membership of Professional Bodies

Fellow of the Chartered Institute of Patent Attorneys (CIPA)

Education

University of Bristol, Honours Degree in Chemistry (Specialist options in Biochemistry)

European Patent Attorney
UK Chartered Patent Attorney

IAM Patent 1000: The World's Leading Patent Practitioners identifies Simon as a recommended individual' for his expertise in Biotechnology. Simon is reported to have the ear of venture capitalists and is an influential figure in many of Europe's IP organisations.

Simon has over 25 years' experience of patent work, including drafting, filing and prosecuting patent applications throughout the world, but in particular before the European Patent Office (EPO). Simon also handles opposition and appeal work, primarily in the life sciences area.

His technical work has covered pharmaceuticals and vaccines, insulin inhalers, fermentation technology, as well as pharmaceutical and nutritional uses of polyunsaturated fatty acids (PUFAs), astaxanthin, and Vitamin B12. He also handles cases on gene therapy, CRISPR technology, botilinum toxin compositions, personalised nutrition, biofuels, nanoparticle/liposome formulations, biomarkers, micro-arrays and stem cells.

Simon's clients range from European multinational companies to small UK academic organisations and SMEs.

He has been involved in oppositions and appeals concerning human pheromones, Hoffman-La Roche's PCR patents, ultrasound contrast agents, medical devices (for measuring glucose levels), nutritional uses of arachidonic acid (ARA), vaccines and anti-prolactin agents.

Simon was involved in the seminal EPO Board of Appeal Decision T820/92 concerning contraceptive methods using LHRH.

He also acted as an expert witness, and so gave evidence to the UK High Court, in the HGS vs Eli Lilly litigation, which led to the first ever Supreme Court decision on the standard of industrial applicability.

Simon joined J A Kemp in 1994, after working elsewhere in private practice since 1986, and became a partner in 1999.

Search by Name or Specialism

OR